Induction of labour.
Dean Leduc, Anne Biringer, Lily Lee, Jessica Dy
Index: J. Pept. Sci. 13 , 742-748, (2007)
Full Text: HTML
Abstract
To review the most current literature in order to provide evidence-based recommendations to obstetrical care providers on induction of labour.Intervention in a pregnancy with induction of labour.Appropriate timing and method of induction, appropriate mode of delivery, and optimal maternal and perinatal outcomes.Published literature was retrieved through searches of PubMed, CINAHL, and The Cochrane Library in 2010 using appropriate controlled vocabulary (e.g., labour, induced, labour induction, cervical ripening) and key words (e.g., induce, induction, augmentation). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date or language restrictions. Searches were updated on a regular basis and incorporated in the guideline to the end of 2010. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.The evidence in this document was rated using criteria described in the Report of the Canadian Task Force on Preventative Health Care (Table 1). SUMMARY STATEMENTS: 1. Prostaglandins E(2) (cervical and vaginal) are effective agents of cervical ripening and induction of labour for an unfavourable cervix. (I) 2. Intravaginal prostaglandins E(2) are preferred to intracervical prostaglandins E(2) because they results in more timely vaginal deliveries. (I).
Related Compounds
Related Articles:
1977-05-01
[J. Biomed. Mater. Res. 11 , 405-422, (1977)]
Self-assembled polypeptide-block-poly(vinylpyrrolidone) as prospective drug-delivery systems
2009-01-01
[Colloids Surf. B Biointerfaces 74 , 284-292, (2009)]
Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Opanasopit P, Yokoyama M, et al.
[Pharmaceut. Res. 21 , 2001-2008, (2004)]